Over view of the program – Cumulative –or- Aggregate reporting, also known as Periodic Reporting, plays a key role in the safety assessment of drugs. Aggregate reporting involves the compilation of safety data for a drug over a prolonged period of time (months or years), as opposed to single-case reporting which, by definition, involves only individual AE reports. The periodic reports plays an important role in risk-benefit evaluation of the drug and involves collective analysis of cases in the database, monitoring regulatory actions, literature searches etc. They are required to be submitted to various regulatory agencies to comply with the regulatory requirements. The advantage of aggregate reporting is that it provides a broader view of the safety profile of a drug.
Join the Workshop in Aggregate Reporting in Drug Safety and Pharmacovigilanceand upgrade your skillset today.
Tuition Fee – $ 999
At the end of this Program you will be able to learn:
Who should enroll?
For more information please contact: